Trial · NCT04392154
Adverse events2,432
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 2,432
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Primary Treatment Period: Lebrikizumab Q4W | 1 | 141 | 1 |
| other | Anaemia | Blood and lymphatic system disorders | Primary Treatment Period: Lebrikizumab Q2W | 6 | 1,012 | 7 |
| other | Anaemia | Blood and lymphatic system disorders | Open-Label Extension Addendum: Lebrikizumab Q4W | 0 | 52 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | Open-Label Extension Addendum: Lebrikizumab Q8W | 0 | 51 | 0 |
| other | Anaemia macrocytic | Blood and lymphatic system disorders | Primary Treatment Period: Lebrikizumab Q4W | 0 | 141 | 0 |
| other | Anaemia macrocytic | Blood and lymphatic system disorders | Primary Treatment Period: Lebrikizumab Q2W | 1 | 1,012 | 1 |
| other | Anaemia macrocytic | Blood and lymphatic system disorders | Open-Label Extension Addendum: Lebrikizumab Q4W | 0 | 52 | 0 |
| other | Anaemia macrocytic | Blood and lymphatic system disorders | Open-Label Extension Addendum: Lebrikizumab Q8W | 0 | 51 | 0 |
| other | Eosinophilia | Blood and lymphatic system disorders | Primary Treatment Period: Lebrikizumab Q4W | 1 | 141 | 1 |
| other | Eosinophilia | Blood and lymphatic system disorders | Primary Treatment Period: Lebrikizumab Q2W | 10 | 1,012 | 12 |
| other | Eosinophilia | Blood and lymphatic system disorders | Open-Label Extension Addendum: Lebrikizumab Q4W | 0 | 52 | 0 |
| other | Eosinophilia | Blood and lymphatic system disorders | Open-Label Extension Addendum: Lebrikizumab Q8W | 0 | 51 | 0 |
| other | Iron deficiency anaemia | Blood and lymphatic system disorders | Primary Treatment Period: Lebrikizumab Q4W | 1 | 141 | 1 |
| other | Iron deficiency anaemia | Blood and lymphatic system disorders | Primary Treatment Period: Lebrikizumab Q2W | 9 | 1,012 | 10 |
| other | Iron deficiency anaemia | Blood and lymphatic system disorders | Open-Label Extension Addendum: Lebrikizumab Q4W | 0 | 52 | 0 |
| other | Iron deficiency anaemia | Blood and lymphatic system disorders | Open-Label Extension Addendum: Lebrikizumab Q8W | 0 | 51 | 0 |
| other | Leukopenia | Blood and lymphatic system disorders | Primary Treatment Period: Lebrikizumab Q4W | 0 | 141 | 0 |
| other | Leukopenia | Blood and lymphatic system disorders | Primary Treatment Period: Lebrikizumab Q2W | 4 | 1,012 | 4 |
| other | Leukopenia | Blood and lymphatic system disorders | Open-Label Extension Addendum: Lebrikizumab Q4W | 0 | 52 | 0 |
| other | Leukopenia | Blood and lymphatic system disorders | Open-Label Extension Addendum: Lebrikizumab Q8W | 0 | 51 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04392154/events